ELATUS Q&A - Other dieseases and timing
Do we have any data on eyespot?
- We have tried to find eyespot in our trials over the last 3 years and only found it on a couple of occasions at low levels
- Indications are that STL adds a little bit extra over and above the activity delivered by PTZ
Do we have any data on fusarium?
- Yes, we have good activity on fusarium, again mainly from the PTZ component. We have observed white head reduction over and above metconazole based applications at T2
- To reduce DON levels, this needs to be a very specifically timed application of GS63-65 and a late T2 or ‘head and shoulders’ type treatment WILL be too early. If this is required, then a well-timed GS39 T2 application, followed by a well-timed T3 application specifically targeted at ear disease is the best advice.
T2 is the main target, but what about T1?
- Product will work very well at T1 as well, particularly when considering eyespot activity from PTZ, but T2 is where the benefits of the GLA retention, long lasting and particularly brown rust benefits are seen.
- Our biokinetics story shows that we are best positioned at T2 delivering long lasting, complete leaf protection across the whole leaf, inside and out, due to the properties of the molecule and the speed at which it moves through the leaf. With other molecules that move more quickly, the base of the, very important, flag leaf becomes exposed and allows disease to disrupt the flow of water and yield building components into and out of the leaf.